Biotechnology stocks as represented by the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) rallied about 1.9% on Monday on the back of merger and acquisition activity in the space. While the recent bounce in biotech land has …
Biotech company, Biogen Inc.'s BIIB shares were up more than 5% in pre-market trading with the company surpassing earnings expectations by a wide margin. Revenues also surpassed expectations. The company reported second …
Yesterday’s rumored M&A interest in Biogen Inc (NASDAQ:BIIB) spiked the stock 10% in a single day. Now that the euphoria has died down, let’s examine what a realistic takeover number might be. With both Merck and Allergan …
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here. Biogen (NASDAQ: BIIB) announced that its Board of Directors authorized a program to repurchase up to $5 billion of the …
Shares of Biogen common stock trading under "BIIB" will carry the right to receive shares of Bioverativ common stock, if held as of the close of business on January 17, 2017. Shares of Biogen common stock trading under "BIIB WI" will not …
As part of the deal, Cambridge-based Biogen (Nasdaq: BIIB) said it would pay …
BIIB) aimed at developing new antisense therapies for neurological disorders. Under the terms of the deal, Biogen will pay Ionis $1B in cash, including $625M to purchase 11,501,153 shares of Ionis common stock at $54.34 per share and a …